Clinical efficacy and security analysis of DEB-TACE combined with trans arterial infusion of carrelizumab in the therapy of advanced liver cancer

IF 2.5 3区医学 Q2 ONCOLOGY

Seminars in oncology Pub Date : 2025-07-17 DOI:10.1016/j.seminoncol.2025.152393

Yang Chen, Xinxin Zang, Xiaoxuan Zhang, Songyan Zhang

{"title":"Clinical efficacy and security analysis of DEB-TACE combined with trans arterial infusion of carrelizumab in the therapy of advanced liver cancer","authors":"Yang Chen, Xinxin Zang, Xiaoxuan Zhang, Songyan Zhang","doi":"10.1016/j.seminoncol.2025.152393","DOIUrl":null,"url":null,"abstract":"<div><div>To explore the clinical efficacy and security analysis of DEB-TACE combined with carrelizumab in the therapy of advanced liver cancer. This study was prospectively designed. Using a random number table method, 96 patients with advanced liver cancer hospitalized from August 2022 to August 2023 were divided into the DT group (DEB-TACE treatment, n = 48) and the DT-C group (on the basis of the DT group, receiving carrelizumab infusion via hepatic artery, n = 48). The changes of therapeutic effect, serum tumor markers, T lymphocyte subsets, overall survival (OS) and progression-free survival (PFS) and the adverse effect were observed. The ORR and DCR of the DT-C group were higher than that of the DT group (P < 0.05). After 1 month of treatment, CD3+, CD4+ and CD4+/CD8+ were increased and the DT-C group was higher than the DT group (P < 0.001). The CD8+ decreased after 1 month of treatment, and the CD8+ in the DT-C group was significantly lower than that in the DT group (P < 0.001). AFP and PIVKA-II decreased after 1 month of treatment, and the DT-C group was lower than the DT group (P < 0.001). The overall survival (OS) (2-year survival rate 33.33%) and progression-free survival (PFS) (2-year survival rate 18.75%) of the DT-C group were higher than those of the DT group (P < 0.05). There was no difference in the adverse reaction incidence (P > 0.05). DEB-TACE combined with trans arterial infusion of carrelizumab is safe and effective in the treatment of advanced liver cancer. Compared with DEB-TACE alone, this combination therapy results in higher CD3+, CD4+, and CD4+/CD8+ levels, as well as reduced CD8+, AFP, and PIVKA-II levels.</div></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"52 5","pages":"Article 152393"},"PeriodicalIF":2.5000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0093775425000855","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

To explore the clinical efficacy and security analysis of DEB-TACE combined with carrelizumab in the therapy of advanced liver cancer. This study was prospectively designed. Using a random number table method, 96 patients with advanced liver cancer hospitalized from August 2022 to August 2023 were divided into the DT group (DEB-TACE treatment, n = 48) and the DT-C group (on the basis of the DT group, receiving carrelizumab infusion via hepatic artery, n = 48). The changes of therapeutic effect, serum tumor markers, T lymphocyte subsets, overall survival (OS) and progression-free survival (PFS) and the adverse effect were observed. The ORR and DCR of the DT-C group were higher than that of the DT group (P < 0.05). After 1 month of treatment, CD3⁺, CD4⁺ and CD4⁺/CD8⁺ were increased and the DT-C group was higher than the DT group (P < 0.001). The CD8+ decreased after 1 month of treatment, and the CD8+ in the DT-C group was significantly lower than that in the DT group (P < 0.001). AFP and PIVKA-II decreased after 1 month of treatment, and the DT-C group was lower than the DT group (P < 0.001). The overall survival (OS) (2-year survival rate 33.33%) and progression-free survival (PFS) (2-year survival rate 18.75%) of the DT-C group were higher than those of the DT group (P < 0.05). There was no difference in the adverse reaction incidence (P > 0.05). DEB-TACE combined with trans arterial infusion of carrelizumab is safe and effective in the treatment of advanced liver cancer. Compared with DEB-TACE alone, this combination therapy results in higher CD3+, CD4+, and CD4+/CD8+ levels, as well as reduced CD8+, AFP, and PIVKA-II levels.

查看原文本刊更多论文

DEB-TACE联合经动脉输注卡瑞珠单抗治疗晚期肝癌的临床疗效及安全性分析

探讨DEB-TACE联合卡瑞珠单抗治疗晚期肝癌的临床疗效及安全性分析。本研究采用前瞻性设计。采用随机数字表法，将2022年8月至2023年8月住院的96例晚期肝癌患者分为DT组（DEB-TACE治疗，n = 48）和DT- c组（在DT组的基础上，经肝动脉输注卡瑞珠单抗，n = 48）。观察两组治疗效果、血清肿瘤标志物、T淋巴细胞亚群、总生存期（OS）、无进展生存期（PFS）及不良反应的变化。DT- c组的ORR和DCR均高于DT组（P <； 0.05）。治疗1个月后CD3+、CD4+、CD4+/CD8+均升高，且DT- c组高于DT组（P <； 0.001）。治疗1个月后CD8+下降，DT- c组CD8+明显低于DT组（P <； 0.001）。治疗1个月后，AFP和PIVKA-II降低，DT- c组低于DT组（P <； 0.001）。DT- c组总生存率（OS）（2年生存率33.33%）和无进展生存率（PFS）（2年生存率18.75%）均高于DT组（P <； 0.05）。两组不良反应发生率比较差异无统计学意义（P >； 0.05）。DEB-TACE联合经动脉输注卡瑞珠单抗治疗晚期肝癌安全有效。与单独使用DEB-TACE相比，这种联合治疗导致CD3+、CD4+和CD4+/CD8+水平升高，CD8+、AFP和PIVKA-II水平降低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in oncology 医学-肿瘤学

CiteScore

6.60

自引率

0.00%

发文量

审稿时长

104 days

期刊介绍： Seminars in Oncology brings you current, authoritative, and practical reviews of developments in the etiology, diagnosis and management of cancer. Each issue examines topics of clinical importance, with an emphasis on providing both the basic knowledge needed to better understand a topic as well as evidence-based opinions from leaders in the field. Seminars in Oncology also seeks to be a venue for sharing a diversity of opinions including those that might be considered "outside the box". We welcome a healthy and respectful exchange of opinions and urge you to approach us with your insights as well as suggestions of topics that you deem worthy of coverage. By helping the reader understand the basic biology and the therapy of cancer as they learn the nuances from experts, all in a journal that encourages the exchange of ideas we aim to help move the treatment of cancer forward.